Erscheinungsjahr
Format
Lizenz
Sprache
-
Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report
Freier ZugriffKarger Verlag | 2024|Schlagwörter: Metastatic castration-resistant prostate cancer -
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Freier ZugriffTaylor & Francis Verlag | 2024|Schlagwörter: Metastatic castration resistant prostate cancer -
Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer
Freier ZugriffDOAJ | 2024|Schlagwörter: metastatic castration-resistant prostate cancer -
Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [177Lu]Lu-PSMA-617 Radioligand Therapy
Freier ZugriffThieme Verlag | 2024|Schlagwörter: metastatic castration-resistant prostate cancer -
Comparison of quantitative whole body PET parameters on [68Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer
Freier ZugriffDOAJ | 2024|Schlagwörter: Metastatic castration-resistant prostate cancer (mCRPC) -
Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta‐analysis
Wiley | 2023|Schlagwörter: non‐metastatic castration‐resistant prostate cancer, metastatic castration‐resistant prostate cancer -
Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry
Freier ZugriffDataCite | 2023|Schlagwörter: Metastatic castration-resistant prostate cancer -
Der DeRitis Quotient als prognostischer Faktor des metastasierten kastrationsresistenten Prostatakarzinoms unter Radioligandentherapie mit 177Lutetium-PSMA
DataCite | 2023|Schlagwörter: metastatic castration-resistant prostate cancer -
Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer
Freier ZugriffWiley | 2023|Schlagwörter: metastatic castration‐resistant prostate cancer -
Long‐term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy‐naïve patients with metastatic castration‐resistant prostate cancer
Wiley | 2023|Schlagwörter: metastatic castration‐resistant prostate cancer -
Breaking through resistance in mCRPC: Enzalutamide analogues as effective anticancer agents for enhanced male survival
Freier ZugriffDOAJ | 2023|Schlagwörter: Metastatic Castration Resistant prostate cancer -
Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis
Freier ZugriffKarger Verlag | 2023|Schlagwörter: Metastatic castration-resistant prostate cancer -
Der DeRitis Quotient als prognostischer Faktor des metastasierten kastrationsresistenten Prostatakarzinoms unter Radioligandentherapie mit 177Lutetium-PSMA ; The DeRitis ratio as a prognostic factor for metastatic castration-resistant prostate cancer treated with 177Lutetium-PSMA radioligand therapy
Freier ZugriffBASE | 2023|Schlagwörter: metastatic castration-resistant prostate cancer -
Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer
Online Contents | 2023|Schlagwörter: Metastatic castration-resistant prostate cancer -
Genomic characterization of metastatic castration‐resistant prostate cancer patients undergoing PSMA radioligand therapy: A single‐center experience
Wiley | 2023|Schlagwörter: metastatic castration‐resistant prostate cancer -
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Taylor & Francis Verlag | 2023|Schlagwörter: metastatic castration-resistant prostate cancer -
Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway
Online Contents | 2023|Schlagwörter: Metastatic castration-resistant prostate cancer -
Apalutamide for prostate cancer: Multicentre and multidisciplinary real‐world study of 227 patients
Freier ZugriffWiley | 2023|Schlagwörter: high‐risk non‐metastatic castration‐resistant prostate cancer -
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
Freier ZugriffOnline Contents | 2023|Schlagwörter: Metastatic castration-resistant prostate cancer (mCRPC) -
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects
Taylor & Francis Verlag | 2023|Schlagwörter: metastatic castration-resistant prostate cancer (mCRPC)
Meine Suche schicken an (beta)
Schicken Sie ihre Suchanfrage (Suchterm ohne Filter) an andere Datenbanken, Portale und Kataloge, um ggf. weitere interessante Treffer zu finden:
Dimensions ist eine Datenbank für Abstracts und Zitate, die Informationen zu Forschungsförderungen mit daraus resultierenden Veröffentlichungen, Studien und Patenten verknüpft.
Im TIB AV-Portal können audiovisuelle Medien aus Wissenschaft und Lehre recherchiert und eigene wissenschaftliche Videos publiziert werden.
Im FID move kann nach fachspezifischer Literatur, Forschungsdaten und weitere Informationen aus der Mobilitäts- und Verkehrsforschung gesucht werden.
Der Open Research Knowledge Graph liefert strukturiert beschriebene Forschungsinhalte und macht diese vergleichbar.
Frei zugänglicher Ausschnitt der Verbunddatenbank K10plus des GBV und des SWB mit für die Fernleihe und Direktlieferdienste relevanten Materialien.